Contents. Welcome Address... iii EULAR 2017 Abstracts Reviewers... iv. Speakers Abstracts

Transcription

1 vi Welcome Address... iii EULAR 2017 Abstracts Reviewers... iv Speaker Presentations Speakers Abstracts Wednesday, 14 June 2017 SP0001 SP0004 Joint EULAR - APLAR session: novel animal models - where no researcher has gone before SP0005 SP0008 Health professional welcome session... 2 SP0009 WIN & HOT session... 3 SP0010 SP0012 Moving towards new criteria in SLE, Sjögren s and APS... 4 SP0013 SP0016 The differential diagnosis of diffuse skin sclerosis and of Raynaud s phenomenon and a practical approach to assessment... 5 SP0017 SP0018 Controling the balance between cancer and autoimmunity... 5 SP0019 SP0021 Fibromyalgia: a disease of the peripheral or central nervous system... 6 SP0022 Chondrocyte channels (role in mechanotransduction)or channeling the chondrocyte... 6 SP0023 SP0024 Wearable technologies in 21 st century healthcare... 7 SP0025 SP0027 Assessment and management of osteoporosis... 7 SP0028 SP0030 Systematic literature review: the link from science to clinical practice... 8 SP0031 SP0033 EULAR Campaign: Don t Delay, Connect Today... 8 SP0034 SP0036 Standing Committee session on paediatric rheumatology... 9 SP0037 SP0040 Ultrasound basic I&II SP0041 SP0043 Rehabilitation and modern drug treatment - needs and challenges SP0044 SP0046 Comorbidities: having one RMD is enough - we don t need anything else SP0047 SP0049 Cytokines and chemokines SP0050 SP0052 Bringing rheumatology research to the next level: addressing the main challenges of patient partnerships in research and health care service design SP0053 WIN & HOT session SP0054 SP0056 Treat-to-target in axspa: reality or utopy? SP0057 SP0058 Calcium crystal deposition in rheumatic diseases SP0059 SP0060 Fifty shades of remission in RA SP0061 SP0063 Innate immunity SP0064 SP0066 To be and to become: transition from paediatric to adult care SP0067 SP0068 Heterogeneity in JIA SP0069 SP0070 EULAR - EMA session SP0071 SP0073 Barrier free employment for young people with RMDs SP0074 Epidemiology of rheumatic and musculoskeletal diseases -acritical appraisal SP0075 SP0077 Ultrasound advanced I&II SP0078 SP0079 PsA: an integrated perspective SP0080 Autoinflammatory diseases in children and adults SP0081 SP0083 Immunogenicity of biologics; myth or reality? SP0084 SP0085 Which target / outcome is more relevant in the management of SLE? SP0086 SP0087 Joint EULAR - EFIS session: Tilting the balance: from disease to tolerance induction SP0088 SP0090 What to do about comorbidity? SP0091 Data visualisation: tables and graphs for publication and presentation I& II SP0092 SP0094 Difficult to reach patient groups SP0095 SP0097 EULAR Projects in musculoskeletal imaging... 24

2 vii SP0098 SP0100 Capillaroscopy I & II SP0101 SP0103 Ultrasound, clinical, diagnostic and therapeutic skills I& II SP0104 SP0105 Macrophage M2 polarization: implications in fibrotizing diseases SP0106 Mucosal B cells: gatekeepers of immune function SP0107 WIN & HOT session SP0108 Comorbidities in rheumatoid arthritis SP0109 SP0110 Life-threatening presentation of rheumatic diseases SP0111 AxSpA: From bug to gut and to disease phenotype SP0112 SP0114 Pregnancy meets rheumatic patients SP0115 SP0116 Neuronal and hormonal alterations in arthritis SP0117 SP0120 Fighting osteoporosis fragilities SP0121 SP0122 Biological agents in juvenile idiopathic arthritis: open issues SP0123 SP0124 Health equity and economy - a vital relationship SP0125 SP0127 Biomarkers in cardiovascular rheumatology - state-of-the-art SP0128 SP0129 MRI I & II SP0130 WIN & HOT session SP0131 SP0133 What is behind vasculitis? SP0134 Cytokine taxonomy: reflection in the therapy of arthritides and other IMIDs SP0135 SP0137 Regulatory molecules in connective tissue SP0138 SP0140 Patient engagement in research: best practices, benefits, and challenges SP0141 SP0142 RA treatment in patients wanting to become pregnant - interactive session SP0143 SP0144 Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of Biosimilars in RMDs SP0145 SP0148 From pre-ra to established RA SP0149 Laboratory course - from the clinic to the lab and back II SP0150 SP0151 Switching T on and off: how T cells drive and regulate chronic inflammation SP0152 SP0153 Reverse translation - learning from clinical trials in SLE, Sjögren s and APS SP0154 SP0156 Genomic imprinting and post-translational modifications SP0157 SP0158 Optimizing treatment for osteoarthritis: take the phenotype in account one size does not fit all.. 38 SP0159 SP0162 Targeting adipose tissue inflammation SP0163 SP0165 Trials and tribulations of medication adherence SP0166 Outcome in juvenile idiopathic arthritis SP0167 Getting financial support to research in RMDs through horizon 2020: opportunities, good practices, and successful experiences SP0168 SP0171 EULAR Projects - challenging projects in education and training SP0172 SP0174 Workshop: strengthening your organisation - how to manage volunteers SP0175 WIN & HOT session SP0176 SP0177 Systemic sclerosis SP0178 How diet influences musculoskeletal diseases SP0179 SP0180 Can targeting disease activity in hand osteoarthritis improve our treatment in the 21 st century SP0181 SP0184 Why we do develop autoimmunity SP0185 SP0188 Closing the gap between objective measures and self-report in fibromyalgia SP0189 Interactive cases from the HOT and WIN sessions SP0190 Suffering in silence. Optimizing the management of psychological well-being for people with RMDs SP0191 SP0194 Showcasing the EULAR Online Course for Health Professionals SP0195 HPR Highlight session... 47

3 viii Scientific Abstracts Oral Presentations Wednesday, 14 June 2017 OP0001 OP0002 Moving towards new criteria in SLE, Sjögren s and APS OP0003 OP0004 Controlling the balance between cancer and autoimmunity OP0005 OP0006 Fibromyalgia: a disease of the peripheral or central nervous system OP0007 OP0008 Chondrocyte channels (role in mechanotransduction) or channeling the chondrocyte OP0009-HPR Wearable technologies in 21 st century healthcare OP0010 Assessment and management of osteoporosis OP0011 Systematic literature review: the link from science to clinical practice OP0012-PARE EULAR Campaign: Don t Delay, Connect Today OP0013 OP0014 Standing Committee session on paediatric rheumatology OP0015 OP0022 Still breaking news on TNF inhibitors in rheumatoid arthritis OP0023 OP0030 Progress in managment of SpA OP0031 OP0038 Early diagnosis of systemic sclerosis and myositis: biomarkers and diagnostic tool OP0039 OP0046 SLE, Sjögren s and APS - clinical aspects OP0047 OP0054 Osteoporosis treatment gap, new options and new strategies OP0055-HPR Rehabilitation and modern drug treatment - needs and challenges OP0056 OP0063 Basic and clinical science in paediatric rheumatology OP0064 OP0071 Impact of rheumatic diseases OP0072-PARE Comorbidities: having one RMD is enough - we don t need anything else OP0073 OP0080 Risk factors for developing diseases or comorbidities OP0081 OP0088 Scleroderma, myositis and related syndromes, etiology, pathogenesis OP0089 OP0096 Novel insights in inflammatory mediators OP0097 Cytokines and chemokines OP0098 OP0105 Progress in biological treatment of RA OP0106 OP0113 PsA: a fascinating disease OP0114 OP0121 More or less imaging in axial SpA? OP0122 OP0129 Clinical and therapeutical news in systemic sclerosis OP0130 OP0137 Vasculitis clinical and pathogenic highlights OP0138-HPR OP0145-HPR HPR mind over matter - patients perspectives OP0146 OP0153 RA: really a systemic disease? OP0154 OP0161 Advances in RA and SpA pathophysiology OP0162-PARE OP0163-PARE Bringing rheumatology research to the next level: addressing the main challenges of patient partnerships in research and health care service design OP0164 OP0171 Osteoarthritis: new horizons for treatment OP0172 OP0179 Cellular drivers of inflammation in rheumatic disease OP0180 OP0187 Joint health & joint damage: a tale of three tissues OP0188 OP0189 Treat-to-target in axspa: reality or utopy? OP0190 OP0191 Calcium crystal deposition in rheumatic diseases OP0192 Fifty shades of remission in RA OP0193 OP0194 Innate immunity OP0195 To be and to become: transition from paediatric to adult care OP0196 OP0197 Heterogeneity in JIA OP0198-PARE OP0199-PARE Barrier free employment for young people with RMDs OP0200 Epidemiology of rheumatic and musculoskeletal diseases -acritical appraisal OP0201 OP0202 PsA: an integrated perspective OP0203 OP0204 Immunogenicity of biologics; myth or reality? OP0205 OP0206 Which target / outcome is more relevant in the management of SLE? OP0207 OP0208 Joint EULAR - EFIS session: tilting the balance: from disease to tolerance induction OP0209-HPR What to do about comorbidity? OP0210-PARE OP0211-PARE Difficult to reach patient groups OP0212 OP0213 Macrophage M2 polarization: implications in fibrotizing diseases

4 ix OP0214 OP0215 Mucosal B cells: gatekeepers of immune function OP0216 OP0223 PsA: the options grow! OP0224 LB0003 From classics to new: synthetic DMARDs in RA OP0231 LB0002 New treatments in SLE, Sjögren s and APS OP0238 OP0245 Axial spondyloarthritis from risk factors to clinical outcomes OP0246 OP0253 RA - causes and courses OP0254-HPR OP0261-HPR HPR move to improve OP0262 OP0269 Gout: advances in diagnosis and management OP0270 LB0001 Low back pain and fibromyalgia OP0276-PARE OP0282-PARE PARE abstract session OP0283 OP0290 Imaging and treamtent response in rheumatology OP0291 OP0298 From genetics through epigenetics to proteomics: understanding disease mechanisms OP0299 OP0306 Innovative insights into mechanism of SLE, Sjögren s and APS OP0307 OP0308 Comorbidities in rheumatoid arthritis OP0309 AxSpA: from bug to gut and to disease phenotype OP0310 OP0311 Pregnancy meets rheumatic patients OP0312 OP0313 Neuronal and hormonal alterations in arthritis OP0314-HPR Fighting osteoporosis fragilities OP0315 OP0316 Biological agents in juvenile idiopathic arthritis: open issues OP0317-PARE OP0318-PARE Health equity and economy - a vital relationship OP0319 Biomarkers in cardiovascular rheumatology - state-of-the-art OP0320 OP0321 What is behind vasculitis? OP0322 Cytokine taxonomy: reflection in the therapy of arthritides and other IMIDs OP0323 OP0324 Personalised care for back pain OP0325 OP0326 Regulatory molecules in connective tissue OP0327-PARE Patient engagement in research: best practices, benefits and challenges OP0328-PARE Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of biosimilars in RMDs OP0329 OP0330 Switching T on and off: how T cells drive and regulate chronic inflammation OP0331 Reverse translation - learning from clinical trials in SLE, Sjögren s and APS OP0332 OP0333 Genomic imprinting and post-translational modifications OP0334 OP0335 Optimizing treatment for osteoarthritis: take the phenotype in account one size does not fit all OP0336 Targeting adipose tissue inflammation OP0337-HPR Trials and tribulations of medication adherence OP0338 Outcome in juvenile idiopathic arthritis OP0339 Systemic sclerosis OP0340 How diet influences musculoskeletal diseases OP0341 OP0342 Can targeting disease activity in hand osteoarthritis improve our treatment in the 21 st century OP0343 Why we do develop autoimmunity OP0344-HPR Closing the gap between objective measures and self-report in fibromyalgia OP0345-PARE OP0346-PARE Suffering in silence. Optimizing the management of psychological well-being for people with RMDs OP0347-HPR Showcasing the EULAR Online Course for Health Professionals Late Breaking Abstracts LB0001 Low back pain and fibromyalgia LB0002 New treatments in SLE, Sjögren s and APS LB0003 From classics to new: synthetic DMARDs in RA

5 x Poster Presentations T1: THU0001 THU0010 Genetic basis, egpigenetics an genomics in disease T2: THU0025 THU0034 Inflammatory mediators in rheumatic disease T3: THU0068 THU0077 RA disease course and prognosis T4: THU0168 THU0176 MTX, GCs and JAK inhibitors in RA T5: THU0216 THU0225 Pathomechanism in SLE, SS, APS T6: THU0246 THU0257 Novelty in the clinical approach to SLE, Sjögren s and APS I T7: THU0294 THU0303 Vasculities clinical aspects I T8: THU0345 THU0354 Progress in managment of spondyloarthritis T9: THU0401 THU0410 A stroll among the crystals T10: THU0486 THU0495 Paediatric rheumatology T11: THU0538 THU0547 Clinicial features and treatment of orphan diseases T12: THU0596 THU0605 Rheumatology training and disease burden T13: THU0648 THU0657 Economical impact of biosimilars and sicussing risks with patients T14: THU0695 THU0704 Outcomes across all rheumatology THU0001 THU0024 Genomics, genetic basis of disease and HLA / T cell recognition THU0025 THU0067 Cytokines and inflammatory mediators THU0068 THU0115 Rheumatoid arthritis - prognosis, predictors and outcome THU0116 THU0167 Rheumatoid arthritis - comorbidity and clinical aspects THU0168 THU0215 Rheumatoid arthritis - non biologic treatment THU0216 THU0245 SLE, Sjögren s and APS - etiology, pathogenesis and animal models THU0246 THU0293 SLE, Sjögren s and APS - clinical aspects (other than treatment) THU0294 THU0344 Vasculitis THU0345 THU0400 Spondyloarthritis - treatment THU0401 THU0467 Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis THU0468 THU0483 Fibromyalgia THU0484 THU0485 Basic science in paediatric rheumatology THU0486 THU0537 Paediatric rheumatology THU0538 THU0579 Other orphan diseases THU0580 THU0598 Education THU0599 THU0657 Public health, health services research and health economics THU0658 THU0704 Validation of outcome measures and biomarkers THU0705 THU0719 Rehabilitation F1: FRI0022 FRI0031 RA stromal cells - reloaded F2: FRI0129 FRI0138 RA all over the body F3: FRI0179 FRI0190 TNF inhibitors in RA = always and again F4: FRI0212 FRI0222, FRI0178 Trends in non-tnf alpha bilogicals for RA I ,548 F5: FRI0255 FRI0265 Novelty in the clinical approach to SLE, Sjögren s and APS II F6: FRI0303 FRI0312 Vasculities clinical aspects II F7: FRI0353 FRI0362 Scleroderma and myositis: etiology F8: FRI0363 FRI0372 Indexes and predictors in systemic sclerosis and myositis F9: FRI0420 FRI0423, FRI0080 FRI0084 New drivers in RA and SpA pathophysiology ,507 F10: FRI0472 FRI0481 Outcome in AxSpA: does it matter? F11: FRI0524 FRI0533 Osteoporosis risk assessment and treatment: new tools and new strategies F12: FRI0582 FRI0591 What s new in orphan diseases F13: FRI0623 FRI0632 Imaging advances in arthritis - what is new? F14: FRI0683 FRI0692 Risk factors for RMDs or comorbid conditions

6 xi FRI0001 FRI0021 Cartilage, synovium and osteoimmunology FRI0022 FRI0084 Rheumatoid arthritis - etiology, pathogenesis and animal models FRI0085 FRI0128 Rheumatoid arthritis - prognosis, predictors and outcome FRI0129 FRI0177 Rheumatoid arthritis - comorbidity and clinical aspects FRI0178 FRI0211 Rheumatoid arthritis - anti-tnf therapy FRI0212 FRI0254 Rheumatoid arthritis - other biologic treatment FRI0255 FRI0302 SLE, Sjögren s and APS - clinical aspects (other than treatment) FRI0303 FRI0352 Vasculitis FRI0353 FRI0362 Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models 620 FRI0363 FRI0419 Scleroderma, myositis and related syndromes FRI0420 FRI0429, FRI0431 Spondyloarthritis - etiology, pathogenesis and animal models , 649 FRI0430 FRI0481 Spondyloarthritis - clinical aspects (other than treatment) FRI0482 FRI0523 Psoriatic arthritis FRI0524 FRI0581 Osteoporosis FRI0582 FRI0622 Other orphan diseases FRI0623 FRI0682 Diagnostics and imaging procedures FRI0683 FRI0731 Epidemiology, risk factors for disease or disease progression S1: SAT0010 SAT0019 Innate mediators and autoantibodies in rhematic disease S2: SAT0027 SAT0036 How B and T cells contribute to rheumatic disease S3: SAT0037 SAT0046 RA - risk factors and consequences S4: SAT0088 SAT0097 From the heart of rheumatology S5: SAT0176 SAT0187 Trends in non-tnf alpha bilogicals for RA II S6: SAT0219 SAT0230 New treatment options in SLE, Sjögren s and APS S7: SAT0312 SAT0321 SSc, myositis and rare diseases: etiology and animal models S8: SAT0372 SAT0381 Last news on systemic sclerosis and myositis S9: SAT0433 SAT0441 A walk through PsA progress S10: SAT0483 SAT0494 Steps forward in osteoarthritis research S11: SAT0556 SAT0565 Infection related rheumatic disease: clinical and epidemiologic aspects S12: SAT0609 SAT0618 Imaging advances in vasculitis, crystal and connective tissue disease S13: SAT0669 SAT0678 Comorbidities and outcomes in RMDs SAT0001 SAT0016 Innate immunity in rheumatic diseases SAT0017 SAT0036 Adaptive immunity (T cells and B cells) in rheumatic diseases SAT0037 SAT0087 Rheumatoid arthritis - prognosis, predictors and outcome SAT0088 SAT0139 Rheumatoid arthritis - comorbidity and clinical aspects SAT0140 SAT0175 Rheumatoid arthritis - anti-tnf therapy SAT0176 SAT0218 Rheumatoid arthritis - other biologic treatment SAT0219 SAT0261 SLE, Sjögren s and APS - treatment SAT0262 SAT0311 SLE, Sjögren s and APS - clinical aspects (other than treatment) SAT0312 SAT0324 Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models 890 SAT0325 SAT0381 Scleroderma, myositis and related syndromes SAT0382 SAT0432 Spondyloarthritis - clinical aspects (other than treatment) SAT0433 SAT0482 Psoriatic arthritis SAT0483 SAT0555 Osteoarthritis SAT0556 SAT0582 Infection-related rheumatic diseases SAT0583 SAT0608 Back pain, mechanical musculoskeletal problems, local soft tissue disorders SAT0609 SAT0668 Diagnostics and imaging procedures SAT0669 SAT0716 Epidemiology, risk factors for disease or disease progression Abstracts Accepted for Publication AB0001 AB0009 Genomics, genetic basis of disease and HLA / T cell recognition AB0010 AB0020 Adaptive immunity (T cells and B cells) in rheumatic diseases

7 xii AB0021 AB0025 Innate immunity in rheumatic diseases AB0026 AB0058 Cytokines and inflammatory mediators AB0059 AB0075 Cartilage, synovium and osteoimmunology AB0076 AB0111 Rheumatoid arthritis - etiology, pathogenesis and animal models AB0112 AB0120 Spondyloarthritis - etiology, pathogenesis and animal models AB0121 AB0163 SLE, Sjögren s and APS - etiology, pathogenesis and animal models AB0164 AB0186 Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models 1104 AB0187 AB0188 Basic science in paediatric rheumatology AB0189 AB0289 Rheumatoid arthritis - prognosis, predictors and outcome AB0290 AB0373 Rheumatoid arthritis - comorbidity and clinical aspects AB0374 AB0394 Rheumatoid arthritis - anti-tnf therapy AB0395 AB0416 Rheumatoid arthritis - other biologic treatment AB0417 AB0441 Rheumatoid arthritis - non biologic treatment AB0442 AB0470 SLE, Sjögren s and APS - treatment AB0471 AB0548 SLE, Sjögren s and APS - clinical aspects (other than treatment) AB0549 AB0597 Vasculitis AB0598 AB0682 Scleroderma, myositis and related syndromes AB0683 AB0708 Spondyloarthritis - treatment AB0709 AB0736 Spondyloarthritis - clinical aspects (other than treatment) AB0737 AB0794 Psoriatic arthritis AB0795 AB0819 Osteoarthritis AB0820 AB0860 Osteoporosis AB0861 AB0901 Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis AB0902 AB0922 Infection-related rheumatic diseases AB0923 AB0932 Fibromyalgia AB0933 AB0943 Back pain, mechanical musculoskeletal problems, local soft tissue disorders AB0944 AB0975 Paediatric rheumatology AB0976 AB0996 Other orphan diseases AB0997 AB1074 Diagnostics and imaging procedures AB1075 AB1115 Public health, health services research and health economics AB1116 AB1160 Epidemiology, risk factors for disease or disease progression AB1161 AB1176 Validation of outcome measures and biomarkers AB1177 AB1182 Rehabilitation AB1183 AB1194 Education Oral Presentations Health Professionals in Rheumatology Abstracts Wednesday, 14 June 2017 OP0009-HPR Wearable technologies in 21 st century healthcare OP0055-HPR Rehabilitation and modern drug treatment - needs and challenges OP0138-HPR OP0145-HPR HPR mind over matter - patients perspectives OP0209-HPR What to do about comorbidity? OP0254-HPR OP0261-HPR HPR move to improve OP0314-HPR Fighting osteoporosis fragilities OP0337-HPR Trials and tribulations of medication adherence OP0344-HPR Closing the gap between objective measures and self-report in fibromyalgia OP0347-HPR Showcasing the EULAR Online Course for Health Professionals

8 xiii Poster Presentations T15: THU0750-HPR THU0759-HPR HPR from top to toe; health professional practice THU0720-HPR THU0751-HPR HPR interventions (educational, physical, social and psychological) THU0752-HPR HPR measuring health (development and measurement properties of PROs, tests, devices) THU0753-HPR THU0755-HPR HPR epidemiology and public health (including prevention) THU0756-HPR THU0757-HPR HPR patients perspectives, functioning and health (descriptive: qualitative or quantitative) 1488 THU0758-HPR HPR professional education, training and competencies THU0759-HPR HPR interventions (educational, physical, social and psychological) THU0760-HPR THU0772-HPR HPR service developments, innovation and economics in healthcare FRI0732-HPR FRI0750-HPR HPR measuring health (development and measurement properties of PROs, tests, devices) FRI0751-HPR FRI0765-HPR HPR epidemiology and public health (including prevention) FRI0766-HPR FRI0772-HPR HPR professional education, training and competencies S14: SAT0717-HPR SAT0725-HPR Nursing and daily practice SAT0717-HPR, SAT0719-HPR, SAT0723-HPR SAT0724-HPR, SAT0726-HPR SAT0770-HPR HPR patients perspectives, functioning and health (descriptive: qualitative or quantitative) , 1511, 1512, 1513 SAT0718-HPR HPR measuring health (development and measurement properties of PROs, tests, devices) SAT0720-HPR HPR service developments, innovation and economics in healthcare SAT0721-HPR SAT0722-HPR HPR epidemiology and public health (including prevention) SAT0725-HPR HPR interventions (educational, physical, social and psychological) Abstracts Accepted for Publication AB1195-HPR AB1207-HPR HPR measuring health (development and measurement properties of PROs, tests, devices) AB1208-HPR AB1214-HPR HPR epidemiology and public health (including prevention) AB1215-HPR AB1230-HPR HPR interventions (educational, physical, social and psychological) AB1231-HPR AB1241-HPR HPR patients perspectives, functioning and health (descriptive: qualitative or quantitative) 1542 AB1242-HPR AB1246-HPR HPR service developments, innovation and economics in healthcare AB1247-HPR AB1249-HPR HPR professional education, training and competencies Oral Presentations People with Arthritis and Rheumatism in Europe Abstracts Wednesday, 14 June 2017 OP0012-PARE EULAR Campaign: Don t Delay, Connect Today OP0072-PARE Comorbidities: having one RMD is enough - we don t need anything else OP0162-PARE OP0163-PARE Bringing rheumatology research to the next level: addressing the main challenges of patient partnerships in research and health care service design

9 xiv OP0198-PARE OP0199-PARE Barrier free employment for young people with RMDs OP0210-PARE OP0211-PARE Difficult to reach patient groups OP0276-PARE OP0282-PARE PARE abstract session OP0317-PARE OP0318-PARE Health equity and economy - a vital relationship OP0327-PARE Patient engagement in research: best practices, benefits and challenges OP0328-PARE Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of biosimilars in RMDs OP0345-PARE OP0346-PARE Suffering in silence. Optimizing the management of psychological well-being for people with RMDs Poster Presentations T16: PARE0001 PARE0011 PARE - Poster tour I F17: PARE0012 PARE0022 PARE - Poster tour II Thursday, 15 June to PARE0001 Building patient led organisations PARE0002 Arthritis research PARE0003 Work and rehabilitation PARE0004 PARE0007 Patient information and education PARE0008 Best practice campaigning PARE0009 Psychosocial support PARE0010 Arthritis research PARE0011 Best practice campaigning PARE0012 PARE0019 Patient information and education PARE0020 PARE0022 Building patient led organisations Abstracts Accepted for Publication AB1250-PARE AB1251-PARE Patient information and education AB1252-PARE AB1253-PARE Best practice campaigning Author Index

10 76 (Suppl 2) Ann Rheum Dis : Updated information and services can be found at: alerting service These include: Receive free alerts when new articles cite this article. Sign up in the box at the top right corner of the online article. Notes To request permissions go to: To order reprints go to: To subscribe to BMJ go to: